Key result
Female sex was associated with a lower prevalence of AF lasting ≥30s compared to male sex during ≤30-day mobile cardiac telemetry (13.7% vs 19.0%, p<0.001).
Why the study?
Women are less likely to receive oral anticoagulation or ablation for AF, but real-world data on sex differences in AF presentation using mobile cardiac telemetry remain scarce.
Are there sex differences in atrial fibrillation prevalence, burden, heart rate, and symptoms among patients undergoing 30-day mobile cardiac telemetry?
Observational (n=27,512)
Are there sex differences in atrial fibrillation prevalence, burden, heart rate, and symptoms among patients undergoing 30-day mobile cardiac telemetry?
Absolute Event Rate: 13.7% vs 19%
p-value: p=<0.001
In real-world ambulatory monitoring, women have a lower prevalence and burden of AF but experience faster heart rates during AF episodes compared to men, with no significant difference in reported symptoms.
Background: Women are less likely to receive oral anticoagulation or ablation for treatment of atrial fibrillation (AF). Identification of sex differences in arrhythmia characteristics and symptoms may lead to a better understanding of potential reasons for these differences. Objectives: To determine sex differences in AF with respect to heart rate, duration, burden, and symptoms in patients undergoing mobile cardiac telemetry (MCT) monitoring. Methods: All patients who registered for ≤30-day MCT using PocketECG (MediLynx) in the USA in 2017 were included (n = 27,512, 58 % women). PocketECG records and transmits a three-lead ambulatory electrocardiogram (ECG) with real-time beat-to-beat analysis. Sex-related differences were analyzed with Chi2 and Spearmans rho. Results: Fewer women than men were diagnosed with AF lasting ≥30s (13.7 % versus [vs] 19.0 %, p < 0.001). AF burden was lower in women in all age groups <90 years (all p < 0.01). Women were older at the time of AF diagnosis (median 76 vs 73 years, p < 0.001), had faster heart rate during AF (mean: 104.7 ± 26.0 vs 96.7 ± 26.7 bpm, p < 0.001), and shorter AF duration (mean: 96.2 ± 176.0 vs 121.6 ± 189.9 min, p < 0.001). There was a non-significant trend toward more symptoms (such as dizziness, racing heart, fatigue, or palpitations) during AF in women compared to men (46.5 % vs 43.7 %, p = 0.062). Conclusions: AF was less prevalent and occurred at lower burdens in women than men in each age strata. Despite faster heart rates in AF in women, there were no significant sex differences in reported symptoms during AF. Sex differences in therapy cannot be explained by differences in symptoms or rates in AF. Condensed abstract: Real-world data on sex differences in AF using a 30-day MCT monitoring device remain scarce. We aim to determine the sex differences in AF with respect to prevalence, burden, heart rate, and symptom in patients undergoing ≤30-day MCT monitoring. Our data analysis suggests that fewer women than men had AF, women were older at diagnosis of AF, and women with AF had higher mean heart rate, shorter mean AF duration, and lower mean AF burden than men. Further studies are needed to examine reasons for sex differences, specifically in relation to AF therapy and its impact on clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2022) conducted an observational in Atrial fibrillation (n=27,512). Female sex vs. Male sex was evaluated on Diagnosis of AF lasting ≥30s (p=<0.001). Female sex was associated with a lower prevalence of AF lasting ≥30s compared to male sex during ≤30-day mobile cardiac telemetry (13.7% vs 19.0%, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: